Kathy Abbott Banner (Kathy Abbott-Banner)

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 4

Top Topics

Ulcerative Colitis

Signaling Pathway

Top Venues

Pharmaceutical research

BMJ open gastroenterology

Clinical and translational science

This page only lists publications with an associated author ORCID identifier.

Publications

Yvonne Boyle, Hemme J Hijma, Jamie Rees, Jagtar Nijjar, Eirini Panoilia, Yolanda Alvarez, Sarah Siederer, Emma Greening, Edward C Emery, Kathy Abbott Banner, Geert Jan Groeneveld
Randomized, placebo-controlled study on the effects of intravenous GSK3858279 (anti-CCL17) on a battery of evoked pain tests in healthy participants. Clinical and translational science 17 (9) (2024)
Debra J Tompson, Mark Whitaker, Rennan Pan, Geoffrey S Johnson, Teresa Fuller, Vanessa Zann, Litza McKenzie, Kathy Abbott Banner, Simon J Hawkins, Marcy Powell
Development of a Once-Daily Modified-Release Formulation for the Short Half-Life RIPK1 Inhibitor GSK2982772 using DiffCORE Technology. Pharmaceutical research 39 (1) (2022)
Debra J Tompson, Mark Whitaker, Rennan Pan, Geoffrey S Johnson, Teresa Fuller, Litza McKenzie, Vanessa Zann, Marcy Powell, Kathy Abbott Banner, Simon J Hawkins
Development of a Prototype, Once-Daily, Modified-Release Formulation for the Short Half-Life RIPK1 Inhibitor GSK2982772. Pharmaceutical research 38 (7) (2021)
Kathy Weisel, Nicola Scott, Scott Berger, Susanne Wang, Kurt Brown, Marcy Powell, Matthijs Broer, Clarissa Watts, Debra J Tompson, Susan W Burriss, Simon Hawkins, Kathy Abbott Banner, Paul Peter Tak
A randomised, placebo-controlled study of RIPK1 inhibitor GSK2982772 in patients with active ulcerative colitis. BMJ open gastroenterology 8 (1) (2021)